Welcome to our dedicated page for Alexandria Real Estate Eq news (Ticker: ARE), a resource for investors and traders seeking the latest updates and insights on Alexandria Real Estate Eq stock.
Alexandria Real Estate Equities, Inc. reports news as a life science real estate investment trust that owns, operates and develops collaborative Megacampus™ ecosystems in major life science innovation clusters. Company updates commonly cover operating results, funds from operations, leasing activity, rental-rate trends and property-market demand across locations such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City.
Recurring announcements also include quarterly common stock dividends, balance-sheet and liquidity commentary, capital recycling activity, senior note offerings, cash tender offers for outstanding debt and corporate governance or leadership matters tied to the REIT’s public-company structure.
Alexandria Real Estate Equities (NYSE: ARE) reported early results of cash tender offers for its 2050, 2051 and 2052 senior notes and has increased the Aggregate Maximum Tender Amount to accept all Notes validly tendered and not withdrawn as of the Early Tender Date (Feb 9, 2026).
As of 5:00 p.m. ET on Feb 9, 2026, holders tendered $497.602M of 3.000% notes due 2051, $524.594M of 3.550% notes due 2052 and $309.199M of 4.000% notes due 2050. Acceptance remains subject to financing conditions.
Alexandria Real Estate Equities (NYSE: ARE) commenced cash tender offers to purchase up to an aggregate purchase price not to exceed $800,000,000 of its outstanding 2051, 2052 and 2050 senior notes.
Offers include an Early Tender Premium of $50 per $1,000, fixed spreads of +75–+80 bps over a 4.750% U.S. Treasury reference, priority acceptance levels, expected settlement in February 2026 and a $500,000,000 financing condition.
Alexandria Real Estate Equities (NYSE: ARE) reported results for the quarter and year ended December 31, 2025. Net loss per diluted share was $(6.35) for 4Q25 and $(8.44) for 2025, while FFO per diluted share, as adjusted was $2.16 for 4Q25 and $9.01 for 2025. The company ended 2025 with 90.9% operating occupancy, $5.30 billion of liquidity, and net debt plus preferred to Adjusted EBITDA of 5.7x (4Q25 annualized).
Actions included a 45% reduction in the quarterly common dividend to $0.72, $1.81 billion of dispositions in 2025, a $500 million repurchase authorization, and reiterated 2026 FFO guidance of $6.25–$6.55 per share.
Alexandria Real Estate Equities (NYSE: ARE) reported the tax composition of its 2025 distributions. Total distributions paid were $5.280000 per share (four quarterly payments of $1.32 each). The taxable ordinary dividend component (Box 1a) totaled $3.517008 per share, representing 66.61% of the total. Qualified dividend amounts totaled $0.762960 per share. Return of capital was $0.033264 per share and Section 199A dividends totaled $0.250008 per share. No Section 897 capital gains were reported. Stockholders are advised to consult their tax advisors for individual treatment.
Alexandria Real Estate Equities (NYSE: ARE) marked its 32nd anniversary on Jan 5, 2026, highlighting its role as a pioneer in life science real estate and Megacampus ecosystems that support drug development and innovation.
Key reported metrics through Sept 30, 2025: 71% of annual rental revenue came from Greater Boston, San Francisco Bay Area, and San Diego; Megacampus occupancy was 91% (+18% vs. market); combined leasing volume in those three markets equaled ~105% of the next five largest owners from Jan 1, 2023–Sept 30, 2025; and five-year average tenant retention exceeded 80%. The company also said 39% of the 44 novel therapies approved by FDA in 2025 were developed or commercialized by Alexandria tenants.
Alexandria plans a public-private partnership MAP-D clinical study targeting a May 2026 launch to identify biomarkers for depression.
Alexandria Real Estate Equities (NYSE: ARE) will host a conference call and audio webcast on Tuesday, January 27, 2026 at 2:00 p.m. ET to discuss its fourth quarter and year end 2025 operating and financial results.
The company will release results after market close on Monday, January 26, 2026. To join the live call dial (833) 366-1125 (U.S./Canada) or (412) 902-6738 (international) and ask the operator for Alexandria Real Estate Equities. The live webcast is available at http://investor.are.com/webcasts.
A replay is available from 4:00 p.m. ET on January 27, 2026 through 4:00 p.m. ET on February 3, 2026; dial (855) 669-9658 (U.S./Canada) or (412) 317-0088 (international) and enter access code 4730896.
Alexandria Real Estate Equities (NYSE: ARE) announced that its Board authorized a refreshed common stock repurchase program of up to $500 million, replacing the prior authorization that was set to expire December 31, 2025.
Under the prior program the company repurchased $258.2 million of common stock, primarily in January 2025. The new authorization permits purchases in the open market or by negotiated transactions, accelerated share repurchases, indirect purchases including derivatives, or other transactions through December 31, 2026. Repurchases are discretionary, may be suspended, and will depend on price, available capital, market and economic conditions. The company said its preference is to fund repurchases on a leverage-neutral basis using operating cash after dividends and proceeds from property dispositions or joint ventures.
Alexandria Real Estate Equities (NYSE: ARE) announced a quarterly cash dividend of $0.72 per common share for 4Q25, a 45% reduction from the 3Q25 dividend. The dividend is payable on January 15, 2026 to holders of record on December 31, 2025. The board said the reduction aims to fortify the balance sheet, enhance financial flexibility and preserve approximately $410 million of liquidity on an annual basis. Based on the closing share price on December 1, 2025, the dividend implies a common-stock yield of 5.4%.
Alexandria Real Estate Equities (NYSE: ARE) reported 3Q25 results for the quarter ended September 30, 2025: Net loss per share diluted $(1.38) and YTD net loss per share diluted $(2.09), while FFO per share diluted, as adjusted was $2.22 for 3Q25 and $6.85 YTD. Operating occupancy was 90.6% with tenant collections at 99.9%. Leasing volume totaled 1.2M RSF in 3Q25, including a 466,598 RSF, 16-year build-to-suit expansion. Liquidity totaled $4.2B; net debt and preferred to Adjusted EBITDA was 6.1x (3Q25 annualized). The board declared a common dividend of $1.32 for 3Q25 (12-month dividend $5.28; yield 6.3%).
Alexandria Real Estate Equities (NYSE: ARE) and Alexandria Venture Investments received the 2025 Charles A. Sanders, MD, Partnership Award from the Foundation for the National Institutes of Health on October 22, 2025.
The award recognizes Alexandria's leadership in launching a public-private precision medicine partnership, MAP-D (Multi-Level Assessment & Phenotyping in Depression), developed with NIMH, FDA, VA, research institutions, industry partners, and patient advocates. MAP-D completed its critical design phase and targets a Phase 1 launch in May 2026 to assemble a comprehensive depression dataset and validate biomarkers to guide individualized treatment.